Photo by Susan Kirby-Smith
Prof Christine Salomon's lecture brings large crowd
CDD signs a licensing agreement for its technology for early detection of Alzheimer's disease
Center for Drug Design (College of Pharmacy, University of Minnesota) has signed an agreement to collaborate with medical imaging startup RetiSpec to commercialize the technology for early detection of Alzheimer’s disease. Read More
Photo by Greta Kaul
Patently lucrative: the intellectual property that makes big money for the U
Compounds developed in Robert Vince’s University of Minnesota lab to combat the HIV virus made the University more than $600 million dollars. Read More
Seeing Alzheimer's disease
A retinal scan technique, developed by researchers in the University’s Center for Drug Design (CDD), has the potential to detect AD in its early stages, when treatment may still be possible, and also to allow doctors to trace the progress of treatments and help the 100,000 Minnesotans with AD and their families. Read More
Message from the Director
The Center for Drug Design (CDD) was created to combine research and scholarship leading to the development of novel drugs for therapeutic applications, such as HIV, cancer, neurological diseases, dermatological agents, infectious diseases, novel processes, and medical devices. The Center for Drug Design combines the best of academic tradition along with an expectation of innovation and independence, and provides significant value for our academic and research community.
Dr. Abel-Santos is interested in research that combines the areas of organic chemistry, biochemistry and microbiology. The Abel-Santos laboratory is currently applying enzymology approaches to the process of Bacillus spore germination for applications in drug discovery and development of anti-anthrax agents.